The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting the strategic push by major pharmaceutical firms to bolster specialized therapy portfolios, Bayer announced the completion of the acquisition and full integration of Perfuse Therapeutics. Through this deal, Bayer now holds full rights to the PER-001 implant, a technology designed for treating Glaucoma and Diabetic Retinopathy. The acquisition aims to strengthen Bayer’s ophthalmology division by securing the rights to this sustained-release small molecule implant.
Sign in to access this content
Sign InThis expansion occurs as the healthcare sector prioritizes innovations that reduce treatment frequency, with Bayer competing against peers like Novartis and Roche in a global ophthalmology market projected to grow at a CAGR of over 6% according to industry reports. The PER-001 asset is currently in Phase II clinical development, positioning Bayer to potentially offer long-term solutions for retinal diseases, which remain leading causes of vision loss worldwide.
Regarding market performance, BAYRY shares stood at $10.38 (close June 16, 2026), after reaching a session high of $10.42 per market data. Investors are now looking toward upcoming clinical trial milestones for the new implant as a primary catalyst, while also monitoring the German CPI data scheduled for June 12 to assess the broader economic impact on European operating costs.